Heaptalk, Jakarta — PT Triman, in collaboration with GC Biopharma Corporation of Korea, represented by PT Medquet Mitra Indonesia (MMI), has established the first Plasma Fractionation Facility in the archipelago in Cikarang, West Java.
By establishing this plasma facility, the President Director of PT Triman, James Setia Dharmawangsa, revealed that this move is expected to increase national health resilience by producing domestically made medicines, whereby the availability of drugs in Indonesia still depends on imported products. Moreover, according to the decision of the Minister of Health of the Republic of Indonesia Number HK.01/MENKES/1349/2023, this company has been stipulated to be the initial Plasma Fractionation Facility.
As is well known, Plasma fractionation is sorting plasma derivatives into plasma products by applying technology in blood processing. In this facility, the company will provide multiple Plasma Derivative Medicinal Products (PDOB) that possess numerous advantages, including:
- Albumin prevents shock in individuals with severe injuries, bleeding, surgery, or burns. On the other hand, this medicine also supports the growth of tissue repair and contributes to removing fluid during dialysis.
- Immunoglobulin, resolving multiple immunodeficiency conditions and several other conditions related to weak body defenses, including autoimmune diseases, infections, and inflammation.
- The Vlll Factor, treating several health issues, including hemophilia, supports normal blood clotting and prevents excessive bleeding.
“This country needs the plasma facility. During the COVID-19 pandemic, numerous people died because they needed the Gammaraas medicine, which is produced by plasma. I realized that this facility is critical to assisting 207 million Indonesians in consuming local medication. To protect our society, we expect the stipulated price to be reasonable for the entire realm,” The Ministry of Health of the Republic of Indonesia.
Supported by the Ministry of Health, BPOM, and PMI, this facility is targeted to be entirely operated in 2024 by processing 200,000 – 400,000 liters of plasma annually. The company will provide around 37,000 liters of plasma annually in collaboration with PMI.
“The General Chairperson of PMI has decided to utilize the remaining plasma through protein separation technology known as fractionation, which will be carried out together with PMI and Medquest Jaya Global.” The Managing Director of PT Medquest Jaya Global, Nanik Gunawan, said.
Translated by Syifa
